Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Short Interest Update

Key Points

• Teva’s short interest surged 11,467.5% to 31.5 million shares as of September 15, representing about 2.7% of shares outstanding and a high short-interest ratio of 27.3 days.
• Insiders sold nearly 375,000 shares worth approximately $14.6 million during the last quarter, including a $14.36 million sale by Director Roberto Mignone.
• Analyst sentiment remains largely positive: 11 analysts rate Teva a Buy, one rates it Hold, and the consensus price target is $43.73, supported by potential growth from its drug pipeline and specialty-medicine portfolio.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 31,478,314 shares, an increase of 11,467.5% from the August 31st total of 272,128 shares. Approximately 2.7% of the shares of the company are short sold. Based on an average daily trading volume, of 1,150,992 shares, the short-interest ratio is currently 27.3 days.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 367,600 shares of the firm's stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the transaction, the insider owned 8,500 shares in the company, valued at approximately $330,225. This trade represents a 46.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 374,959 shares of company stock valued at $14,644,285 in the last quarter. 0.54% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. grew its stake in Teva Pharmaceutical Industries by 2.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company's stock valued at $1,384,216,000 after acquiring an additional 1,004,941 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its stake in Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company's stock valued at $1,171,378,000 after purchasing an additional 5,917,423 shares in the last quarter. WCM Investment Management LLC increased its holdings in Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company's stock worth $1,157,264,000 after buying an additional 26,813,522 shares during the last quarter. Norges Bank bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $1,098,060,000. Finally, Geode Capital Management LLC grew its position in shares of Teva Pharmaceutical Industries by 3.4% in the 4th quarter. Geode Capital Management LLC now owns 10,326,504 shares of the company's stock valued at $320,295,000 after acquiring an additional 336,629 shares during the period. Institutional investors own 54.05% of the company's stock.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Oppenheimer initiated coverage with an “Outperform” rating and a $50 price target, implying meaningful upside from recent trading levels. The firm reportedly views Teva as entering an acceleration phase supported by a multi-year product-launch cycle, although it cited some near-term concerns around Austedo. Oppenheimer Teva coverage article
• Positive Sentiment: Teva’s investigational once-monthly olanzapine long-acting injectable, TEV-749, and its UZEDY schizophrenia treatment remain potential growth drivers. Recent clinical data support investor interest in Teva’s central-nervous-system franchise, though TEV-749 still requires regulatory approval. Teva pipeline update
• Neutral Sentiment: Teva released its Q3 2026 aide memoire and confirmed that third-quarter results will be issued on November 3 before an investor conference call. The materials provide an upcoming catalyst, but do not themselves contain new financial results or guidance. Teva Q3 2026 aide memoire
• Neutral Sentiment: The stock is approximately 4.36% below its yearly high, indicating strong recent momentum but also leaving investors focused on whether upcoming earnings can justify the elevated valuation. Teva stock near yearly high
• Negative Sentiment: Director Roberto Mignone sold 367,600 shares for approximately $14.36 million. The large sale, made after a significant advance in TEVA, could create near-term selling pressure and raise questions about insider confidence. SEC filing for Roberto Mignone share sale
• Negative Sentiment: Interim Chief Legal Officer Brian Savage separately sold 7,342 shares worth about $285,000, reducing his direct ownership by roughly 46%. The additional insider sale reinforces the caution surrounding TEVA’s recent rally. Teva insider selling report

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an "overweight" rating in a report on Tuesday, July 28th. Oppenheimer started coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday. They set an "outperform" rating and a $50.00 price target for the company. Barclays raised their price target on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. Leerink Partners initiated coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They issued an "outperform" rating and a $45.00 price objective for the company. Finally, Weiss Ratings lowered shares of Teva Pharmaceutical Industries from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, September 8th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $43.73.

Teva Pharmaceutical Industries Stock Performance

TEVA traded up $1.17 during trading on Thursday, reaching $40.18. 7,730,889 shares of the company's stock were exchanged, compared to its average volume of 6,865,927. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. The business has a 50 day moving average price of $35.88 and a 200 day moving average price of $33.70. The company has a market capitalization of $46.82 billion, a P/E ratio of 66.97, a PEG ratio of 4.93 and a beta of 0.87. Teva Pharmaceutical Industries has a fifty-two week low of $18.21 and a fifty-two week high of $40.79.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. As a group, analysts predict that Teva Pharmaceutical Industries will post 1.94 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva's specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.